901PImpact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. (23rd October 2018) - Bellmunt, J; de Wit, R; Vaughn, D J; Fradet, Y; Lee, J L; Fong, L; Vogelzang, N J; Climent, M A; Petrylak, D; Choueiri, T K; Necchi, A; Gerritsen, W R; et al.